Controlled clinical trial of prostadyn sabale used in treatment of benign prostatic hyperplasia in 80 patients

AIM: To observe the treatment effects and safety of prostadyn sabale on benign prostatic hyperplasia (BPH). METHODS: One hundred and sixty patients with BPH were divided into two groups, 80 patients in each. The patients in prostadyn sabale group ( age (66±s 7)a) took prostadyn sabale 160 mg, po,bid for 6 mo while the patients in finasteride group (age(66±9)a) took finasteride 5 mg,po,qd for 6 mo. RESULTS: After the treatment, the international prostate symptom score (IPSS) decreased 6.9±0.7 in the prostadyn sabale group, while 6.4±0.7 in the finasteride group,showing no significant difference between the two groups (P0.05), and also with no significant difference in residual volume of urine and Q(max) (P0.05) between two groups. The prostatic volume and prostatic specific antigen(PSA) decreased (8.5±1.0) mL and (1.50±0.20) μg·L~(-1) in the finasteride group, both were higher than those in the prostadyn sabale group ((0.40±(0.09) mL), (0.100±(0.010)) μg·L~(-1)), P0.01. No obvious adverse reactions occurred in both groups. CONCLUSION: Prostadyn sabale is effective and safe in the treatment of BPH.